Not yet recruitingNot applicableNCT06287086

Clinical Study on the Safety and Efficacy of BRL-101 in the Treatment of Sickle Cell Disease

Studying Sickle cell disease

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Bioray Laboratories
Principal Investigator
Jun shi, PhD
Institute of Hematology & Hospital of Blood Diseases, Chinese Academy of Medical Sciences & Peking Union Medical College
Intervention
BRL-101 autologous hematopoietic stem and progenitor cells injection(drug)
Enrollment
1 enrolled
Eligibility
3-35 years · All sexes
Timeline
2024 – 2026

Collaborators

Institute of Hematology & Hospital of Blood Diseases, Chinese Academy of Medical Sciences & Peking Union Medical College

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06287086 on ClinicalTrials.gov

Other trials for Sickle cell disease

Additional recruiting or active studies for the same condition.

See all trials for Sickle cell disease →

← Back to all trials